Alnylam Pharmaceuticals, Inc

For its directly commercialized medicines (AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO), Alnylam’s immediate customers are specialty distributors and healthcare providers, with demand driven by specialist physicians treating rare diseases and ATTR amyloidosis. Patient access is heavily influenced by third-party payors, so payer coverage, reimbursement pathways, and health-system adoption are central to commercialization. In addition to product sales, Alnylam earns revenue from pharmaceutical partners through collaboration arrangements and royalties where collaborators hold commercialization rights (e.g., Leqvio and Qfitlia). The company’s commercial execution depends on educating prescribers, supporting patients, and navigating country-by-country regulatory and market access requirements.

Alnylam’s strategy centers on expanding its RNAi therapeutic platform into a multi-product global business by scaling commercial operations and sequentially launching products across geographies. In ATTR amyloidosis, it is leveraging experience from hereditary ATTR polyneuropathy to drive broader adoption (including cardiomyopathy) through health-system set-up, payer access work, and physician/patient education. The company continues to invest heavily in R&D and late-stage capabilities, while using collaborations with large pharma (e.g., Roche, Regeneron, Sanofi, Novartis/MDCO) to fund development and extend commercialization reach. Management has also articulated a goal of financial self-sustainability, while continuing to expand manufacturing capacity and global compliance capabilities to support growth.